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Murine gammaherpesvirus-68 (MHV-68) induces high levels of interleukin (IL)-6 production in both naive and primed
lymphocyte populations. Mice that are homozygous (2/2) for deletion of the IL-6 gene were used to investigate the role of
this cytokine in MHV-68 infection. The results showed that IL-6 is not essential for clearance of infectious MHV-68 from the
lung or for the establishment, or control, of viral latency. Both IL-6 1/1 and 2/2 mice eliminated replicating virus from the
respiratory tract within 15 days of infection, and their lungs remained clear of infectious virus for $150 days. Interestingly,
the IL-6 2/2 mice had both increased numbers of natural killer (NK)1.11 cells and higher levels of NK cell activity than the
1/1 controls at 10–15 days after infection. However, there was no difference in the cytotoxic T cell activity between the two
groups of mice. Levels of latent virus were comparable in IL-6 1/1 and 2/2 mice over the time course studied. Furthermore,
analysis of the numbers, types, and activation status of the various leukocyte subsets (other than NK cells) in the
bronchoalveolar lavage population, lymph nodes, and spleens of 1/1 and 2/2 mice revealed no striking differences. Apart
from the expected lack of IL-6, cytokine profiles were not dramatically altered in IL-6 2/2 mice. Thus, there is no evidence
for an obligatory role for IL-6 in T cell activation during infection with MHV-68. © 1998 Academic Press
INTRODUCTION
Murine gammaherpesvirus-68 (MHV-68) is a naturally
occurring rodent pathogen (Blaskovic et al., 1980) that
is closely related to Epstein–Barr virus (EBV), Kaposi’s
sarcoma-associated human herpesvirus 8 (HHV-8),
and herpesvirus Saimiri (HVS) (Efstathiou et al., 1990;
Virgin et al., 1997). Intranasal (i.n.) administration of
MHV-68 results in acute productive infection of lung
alveolar epithelial cells and a latent infection in B lym-
phocytes and possibly some other cell types (Ehtisham
et al., 1993; Sunil-Chandra et al., 1992; Usherwood et al.,
1996; Weck et al., 1996). The virus induces an inflamma-
tory infiltrate in the lungs and enlargement of the lymph
nodes and spleen. Infectious virus is cleared from the
lungs by a T cell-mediated process 10–13 days after
infection (Ehtisham et al., 1993). In common with some
other herpesviruses, MHV-68 induces high levels of IL-6
production (Sarawar et al., 1996). The cytokine is pro-
duced by B cells from naive mice and by both B and T
cells from primed mice on in vitro challenge with MHV-
68. Interleukin (IL)-6 has been reported to play a role in
host defense mechanisms such as cytotoxic T cell gen-
eration and B cell growth and differentiation (Lotz et al.,
1988; McGhee et al., 1989; Rogers et al., 1991). However,
IL-6 has also been reported to function as an autocrine
growth factor for EBV-induced lymphoblastoid cell lines
(LCLs) and Kaposi’s sarcoma (Tosato et al., 1990; Miles
et al. 1990) and to inhibit natural killer (NK) cell activity
against EBV LCLs (Tanner and Tosato, 1991). In some
models, IL-6 has been shown to promote inflammation
by the induction of chemokines (Romano et al., 1997).
Thus, IL-6 can induce an array of different effects that
could have potential roles in either viral pathogenesis or
host defense. To determine whether IL-6 plays a unique
role in the immune response to MHV-68, we compared
the course of infection in IL-6 1/1 and 2/2 mice.
RESULTS
Virus titers
Analysis of lung virus titers during MHV-68 infection of
IL-6 1/1 and 2/2 mice showed that there was no
significant difference in the extent of viral growth or rate
of clearance (Fig. 1). Both 1/1 and 2/2 mice had
cleared infectious virus from the lungs 15 days after
inoculation with MHV-68. Peak lung virus titers were
measured at day 6 after infection in both 2/2 and 1/1
mice (Fig. 1). There was no significant difference be-
tween the lung virus titers for 1/1 and 2/2 mice at this
time point or at day 10 after infection, when lung virus
titers were decreasing. The lungs of both groups of mice
remained clear of replicating virus for $150 days after
infection, indicating that the virus was controlled effec-
tively. Mice in both groups appeared healthy at the latter
time point, and the lungs appeared normal on macro-
scopic examination. The detection limit of the plaque
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assay is 10 pfu/ml of a 10% tissue homogenate. In one
experiment, mice were given a higher dose of virus (2 3
106 pfu) i.n. No deaths occurred in either the 1/1 or 2/2
groups. Similarly, there was no significant or consistent
difference in the frequency of latently infected cells in
IL-6 1/1 and 2/2 mice (Fig. 2). Comparable frequen-
cies were found in the mediastinal lymph node (MLN),
which drains the lung; cervical lymph node (CLN); and
spleen of IL-6 1/1 and 2/2 mice at all time points
(Fig. 2). These data suggest that IL-6 is not essential for
viral clearance and does not play a major role in the
establishment of either productive or latent infection.
Development of the inflammatory response in the
absence of IL-6
The cell types and numbers accumulating in the lungs,
lymph nodes, and spleen were determined at various
times after infection (Fig. 3). Both IL-6 1/1 and 2/2
mice showed splenomegaly and lymph node enlarge-
ment and developed inflammatory infiltrates in their
lungs. Peak cell numbers were observed at day 6 after
infection in the lungs, day 15 in the spleen, and days
10–15 in the lymph nodes. There was no significant
difference in the extent or kinetics of cell accumulation in
the lymph node, spleen, or lungs. This suggests that IL-6
is not required for lymphocyte trafficking during MHV-68
infection and that chemokines and surface molecules
that control this process can be induced by other factors.
The cell types contributing to the observed increase in
cell number were also analyzed to determine whether
there were changes in the relative proportions of the
different subsets (Fig. 4). The percentages of CD4 and
CD8 T cells and B cells in the spleen, lymph nodes, and
lungs were similar in IL-6 2/2 and 1/1 mice. However,
interestingly, the proportion of NK cells was higher in the
spleen, bronchoalveolar lavage (BAL), and lymph nodes
of the IL-6 2/2 mice at days 10–15 after infection. In IL-6
1/1 mice, the mean 6 SD percentage of NK cells at day
10 after infection was 0.5 6 0.7 for BAL, 0.6 6 0.2 for
spleen, and 0.8 6 0.5 for MLN. In IL-6 2/2 mice, the
corresponding percentages were 6.4 6 6.7 for BAL,
2.6 6 1.3 for spleen, and 1.3 6 0.9 for MLN. At day 15, the
mean 6 SD percentages were 0.4 6 0.5 for BAL, 1.1 6 1.1
for MLN, and 0.3 6 0.1 for spleen in IL-6 1/1 mice and
2.3 6 1.7 for BAL, 3.0 6 0.8 for spleen, and 2.9 6 0.5 for
MLN in IL-6 2/2 mice. This difference was statistically
significant for BAL (P 5 0.0012 for combined data from
days 10 and 15, Mann–Whitney rank sum test) and
spleen (P , 0.0012, for combined data from days 10 and
15, Mann–Whitney rank sum test). The difference in the
number of NK cells in the mediastinal lymph nodes of
IL-6 2/2 and 1/1 mice was not statistically significant
(P 5 0.097, Mann–Whitney rank sum test). Similar pro-
portions of NK cells were present in the lymph nodes and
spleens of IL-6 2/2 and 1/1 mice before infection, and
there were very few cells of any type in the BAL at this
FIG. 2. Latently infected cells in the spleen and lymph nodes of IL-6
1/1 and 2/2 mice. Results are expressed as mean 1 SD infectious
centers/107 cells for two to four separate experiments at each time
point except for day 150 (all tissues) and MLN at day 35, which were
single experiments. Pooled tissues from three mice were tested at
each time point in each experiment.
FIG. 1. Titers of lytic virus in the lungs of MHV-68-infected IL-6 2/2
and 1/1 mice. Results are expressed as mean 6 SD log10 pfu/ml of a
10% tissue sonicate for three separate experiments at days 6, 10, and
15; two at day 35; and one at day 150. Tissues from 3 mice were tested
at all time points in each experiment.
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stage (data not shown). Because the cell numbers in the
lungs and lymphoid tissues during MHV-68 infection
were similar in the IL-6 2/2 and 1/1 mice, it appeared
that there was an increase in the absolute number of
NK1.1 cells in the various tissues. This suggests that IL-6
may play a role in inhibiting the recruitment or prolifera-
tion of NK cells during MHV-68 infection.
Cytotoxic T cell and NK cell activity during MHV-68
infection
Because increased numbers of NK cells were
present in IL-6 2/2 mice, it was of interest to deter-
mine whether this translated to an increase in NK cell
activity. To address this question, NK cell function was
determined by cytolysis of 51Cr-labeled YAC cells at
various times after infection (Fig. 5). In spleen, BAL,
and MLN, increases in NK cell activity were seen that
paralleled the increased NK cell numbers in IL-6 mice.
Thus, in the present study, IL-6 appeared to be sup-
pressing the accumulation of NK cells rather than
inhibiting their activity. In one experiment, groups of
IL-6 1/1 mice were infected with MHV-68 and treated
with a neutralizing antibody to IL-6 or with an isotope
control antibody. NK cell activity was assayed 4 days
after infection. Consistent with data from IL-6 2/2
mice at days 6 and 10, there was an increase in NK
cell activity in the spleen and BAL of anti-IL-6-treated
mice compared with the controls (Table 1).
Cytotoxic T cell activity was also determined by redi-
rected lysis of FcR1 51Cr-labeled P815 cells in the pres-
ence of a monoclonal antibody (mAb) to CD3. Previous
studies have shown that the majority of the T cell cyto-
lytic activity during MHV-68 infection is mediated by the
CD8 T cell subset (Cardin et al., 1996). No difference was
found between the cytotoxic activity of cells from the
spleen and MLN of IL-6 2/2 and 1/1 mice (Fig. 6).
However, there appeared to be a slight decrease in
cytotoxic T cell activity in the BAL of the IL-6 2/2 group
(Fig. 6).
Cytokine production
Cytokines were assayed in culture supernatants after
in vitro restimulation of splenocytes from virus-infected
or control (day 0) mice. Supernatants were harvested at
24, 72, and 96 h after restimulation. Peak values are
shown and were found at 72 h for all cytokines detected.
The detection limits were 0.4 unit/ml for IL-4 and IL-5, 0.4
ng/ml for IL-10, and 0.8 unit/ml for all other cytokines.
Earlier reports suggested that IL-6 might regulate cy-
tokine profiles. However, in the present study, apart from
the expected lack of IL-6, the IL-6 2/2 mice showed no
significant change in cytokine production (Fig. 7). As
previously shown, little or no IL-4 or IL-5 was detected in
the supernatants of lymph node and spleen cells restim-
ulated in vitro with virus (data not shown). Levels of IL-2
were also very low (data not shown), and there was no
significant change in IL-10 or interferon (IFN)-g produc-
tion (Fig. 7). In agreement with previous data, IL-6 and
IL-10 were produced by both naive and primed cells in
response to the virus, whereas IFN-g was produced only
by primed cells. The results confirmed that the gene for
IL-6 had been fully inactivated in the IL-6 2/2 mice in
FIG. 3. Cell numbers in the spleen, MLN, CLN, and BAL were determined at intervals after i.n. infection of IL-6 2/2 and 1/1 mice with MHV-68.
Single-cell suspensions were prepared from lymphoid tissue from groups of three mice, and viable cell counts were determined by trypan blue
exclusion. Data are mean 1 SEM for three or four separate experiments at each time point.
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that lymph node or spleen cells from the latter failed to
produce IL-6, whereas those from 1/1 mice made sub-
stantial amounts of this cytokine. Thus, IL-6 does not
appear to play an essential role in controlling the overall
cytokine profile.
DISCUSSION
Infection with MHV-68 has been shown previously to
induce high levels of IL-6 production in B cells from naive
mice and in both B and T cells from primed animals
(Sarawar et al., 1996). Because IL-6 has been reported to
play a role in the development of CTL effectors (Rogers
et al., 1991; Lotz et al., 1988), this could represent a host
defense mechanism. However, the lack of effect of IL-6
on CTL activity, or on the clearance of infectious virus in
the present study, suggests that the function of IL-6 is
either insignificant or redundant in MHV-68 infection.
Alternatively, virus-induced IL-6 could enable the virus to
establish and maintain a persistent infection. There is
evidence with another gammaherpesvirus, EBV, that IL-6
stimulates the proliferation and tumorigenicity of virus-
infected B cells (Tanner and Tosato, 1991; Tosato et al.,
1990). However, the lack of IL-6 in the present study did
not result in a decline in the frequency of latently infected
cells or in viral titers, suggesting that IL-6 is not essential
for the establishment or maintenance of infection with
MHV-68. IL-6 has been reported to be an autocrine
growth factor for Kaposi’s sarcoma and for certain B cell
lymphomas (Tosato et al., 1990; Miles et al., 1990). Inter-
estingly, the Kaposi’s sarcoma-associated HHV-8 en-
codes a functional IL-6 homolog (Nicholas et al., 1997).
Although the MHV-68 genome has been sequenced and
FIG. 4. Lymphocyte subsets in the spleen, BAL, and MLN of IL-6 2/2 and 1/1 mice infected with MHV-68 10 or 15 days earlier. Cell suspensions
were prepared and stained with PE or FITC-conjugated mAbs as previously described (Sarawar and Doherty, 1994) and fixed in 1% paraformaldehyde
(Ted Pella Inc., Redding, California) after staining. (TCR) T cell receptor. The results are expressed as mean percentage of positive cells 1 SEM
(determined by flow cytometry) for three or four separate experiments at each time point.
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is closely related to that of HHV-8, no IL-6 homolog was
detected in the former (Virgin et al., 1997). However,
MHV-68 has been reported to induce tumors or lympho-
proliferative disease (Sunil Chandra et al., 1994), and it
would be interesting to determine whether IL-6 plays a
role in MHV-68-induced tumorigenesis. IL-6 has been
shown to inhibit NK cell activity against EBV-infected
targets (Miles et al., 1990), although studies in other
models have variously reported that IL-6 increases, de-
creases, or has no effect on NK cell activity (Malejczyk et
al., 1991; Rabinowich et al., 1993; Dalrymple et al., 1995;
Keever Taylor et al., 1996; Kanda et al., 1996). In the
present study, the lack of IL-6 resulted in increased NK
cell activity. However, this appeared to result from de-
creased numbers of NK cells in lungs and lymphoid
tissues in the IL-6 1/1 mice during infection rather than
from an inhibitory effect of IL-6 on NK cell activity. Inter-
estingly, IL-6 appeared to inhibit the accumulation of NK
cells in that IL-6 2/2 mice had increased numbers of NK
cells and increased NK cell activity during infection with
MHV-68. Similarly, in vivo neutralization of IL-6 in 1/1
mice caused an increase in NK cell activity in the spleen
and BAL. The mechanism by which IL-6 regulates NK cell
numbers in MHV-68-infected mice is currently unknown.
The lack of IL-6 did not affect viral clearance, suggest-
ing that (1) NK cells are not important for viral clearance,
FIG. 5. NK cell activity. Single-cell suspensions were prepared from
groups of three IL-6 2/2 or 1/1 mice, and NK cell activity was
determined in a 6-h 51Cr release assay using YAC cells as targets. The
results shown are for an effector-to-target ratio of 40:1. Data are mean
values for two separate experiments at each time point except for day
35, which was a single experiment. (ND) Not determined.
TABLE 1
The Effect of in Vivo Neutralization of IL-6 on NK Cell Activity
Percent specific lysis
Anti-IL-6 Isotype control
BAL 15.8 8.6
Spleen 7.2 4.5
MLN 6.2 6.1
Note. Groups of three 1/1 or 2/2 mice were infected with 104
pfu/mouse MHV-68 as described in Materials and Methods. Mice were
killed 4 days after infection, and NK cell activity was measured by lysis
of 51Cr-labeled YAC cells.
FIG. 6. Effector cytotoxic T lymphocyte (CTL) activity in the spleen,
MLN, and BAL. Single-cell suspensions were prepared from groups of
3 IL-6 2/2 or 1/1 mice, and CTL activity was determined in a
redirected 6-h 51Cr release assay (E:T, 40:1) using FcR1 P815 cells as
targets. Data are mean values for two separate experiments at each
time point except for day 35, which was a single experiment. (ND) Not
determined.
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(2) the number of NK cells in the lungs and lymphoid
tissues of IL-6 1/1 mice is sufficient to maintain control
of virus, or (3) the increase in NK cells in IL-6 2/2 mice
compensates for another defect in viral control caused
by the lack of IL-6. Studies are in progress to further
delineate the role of NK cells in the host response to
MHV-68.
MATERIALS AND METHODS
Mice
Breeding pairs of 129/B6 mice, which were heterozy-
gous (1/2) for the disruption of the IL-6 gene (Kopf et al.,
1994), were obtained from Dr. Jose Guttierez (Center for
Blood Research, Harvard University, Boston, Massachu-
setts). This strain was originally derived by Dr. Manfred
Kopf (Basel Institute, Basel, Switzerland). Mice were bred
and housed under specific pathogen-free conditions in
the animal resource center at St. Jude Children’s Re-
search Hospital. Some IL-6 2/2 and 1/1 129/B6 mice
were also purchased from Jackson Laboratories (Bar
Harbor, Maine). The genotypes of subsequent littermates
were screened by PCR on tail DNA using the following
primers: 59-IL-6, CCACGCAGGAGACTTCCATC; 39-IL-6,
GGACGCCACACTGGGTCTTC; 59-neo, TCAGCGCAGGG-
GCGCCCGGTTCTTT; and 39-neo, ATCGACAAGACCGGC-
TTCCATCCGA. IL-6 and neo bands were 235 and 375 bp,
respectively. Tail DNA was isolated using a kit from
Qiagen (Chatsworth, CA) according to the manufacturer’s
instructions. The genotypes of IL-6 1/1 or 2/2 mice
were verified by an ELISA for IL-6 using culture super-
natants from cells stimulated in vitro with MHV-68 as
described below. Age- and sex-matched 6–15-week-old
IL-6 1/1 and 2/2 mice were used in all experiments.
Viral infection and sampling
MHV-68 virus (clone G2.4) was obtained from Dr. A. A.
Nash (Edinburgh, UK), and stocks were grown in owl
monkey kidney (OMK) cells (CRL 1556; American Type
Culture Collection, Rockford, Maryland). Mice were
anesthetized with Avertin (2,2,2-tribromoethanol) and in-
fected i.n. with 4000 plaque-forming units (pfu) of the
virus (unless otherwise specified) in phosphate-buffered
saline (PBS). At various times after infection, the mice
were terminally anesthetized with Avertin and bled from
the right axilla or vena cava. The inflammatory cells
infiltrating the lung were harvested by BAL via the tra-
chea, and single-cell suspensions were prepared from
the spleen; MLN, which drains the lung; and CLN, which
drains the head and neck region, as previously de-
scribed (Allan et al., 1990). Cell viability was determined
by trypan blue exclusion. After lavage, the lungs were
removed and sonicated in medium on ice before virus
titration.
In one experiment, a higher dose of virus (2 3 106
pfu/ml) was administered i.n. to groups of four 2/2 or
1/1 mice.
Treatment with antibodies against IL-6 in vivo
In one set of experiments, wild-type (1/1) mice were
simultaneously infected with MHV-68 and treated with
either a neutralizing mAb (MP5–20F3, 0.5 mg/mouse i.p)
or 0.5 mg of rat IgG1 isotype control. Both antibodies
were obtained from PharMingen (San Diego, California).
Virus titration and infectious centers assay
Titers of replicating virus were determined by plaque
assay on NIH 3T3 cells (CRL 1658; American Type Cul-
ture Collection) as described previously (Cardin et al.,
1996). Briefly, dilutions of stock virus or sonicated mouse
tissues were adsorbed onto NIH 3T3 monolayers for 1 h
at 37°C and overlaid with carboxymethyl cellulose
(CMC). After 5 days, the CMC overlay was removed, and
FIG. 7. Cytokine production by in vitro restimulated splenocytes from
MHV-68-infected IL-6 2/2 and 1/1 mice. Spleen cell suspensions
were prepared and restimulated in vitro with virus-infected irradiated
spleen cells. Cytokines were assayed in the culture supernatants by
sandwich ELISA as described previously (Sarawar and Doherty, 1994).
The detection limit was ,0.4 unit/ml for IL-4 and IL-5, 0.4 ng/ml for
IL-10, and ,0.8 unit/ml for the other cytokines. Data are mean 1 SEM
for three separate experiments at days 6–35 and two experiments at
day 0. No IL-2, IL-4, or IL-5 was detected.
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the monolayers were fixed with methanol and stained
with Giemsa to facilitate determination of the number of
plaques. The detection limit of this assay was 10 pfu/ml
of a 10% tissue homogenate based on plaques recovered
from homogenates of uninfected tissues spiked with
known amounts of virus.
The frequency of latently infected lymphocytes was
determined using an infectious centers assay. Leukocyte
suspensions prepared from lymph nodes or spleen were
plated at various cell densities onto monolayers of NIH
3T3 cells, incubated overnight, and then overlaid with
CMC. The cells were cocultured for 5–6 days, after which
the overlay was removed, and the number of plaques
was determined as described above.
Cytotoxicity assays
Cytotoxic T cell activity was determined using a redi-
rected assay on suspensions of lymph node, spleen, or
BAL cells. The BAL cells were incubated in Petri dishes
for 1 h at 37°C to remove macrophages by plastic adhe-
sion. Cell suspensions were incubated with 51Cr-labeled
P815 cells in the presence of the 2C11 mAb to CD3 for
6 h at 37°C as previously described (Cardin et al., 1996).
The level of specific 51Cr release is a measure of the total
(virus-specific and -nonspecific) cytotoxicity.
NK cell activity was determined by the release of 51Cr
from labeled YAC cells as previously described (Allan et
al., 1990)
Flow cytometric analysis
Cells were stained with phycoerythrin (PE) or fluores-
cein (FITC)-conjugated mAbs as previously described
(Sarawar and Doherty, 1994). All antibodies were pur-
chased from PharMingen. Isotype controls were in-
cluded in each assay.
Cytokine ELISAs
Cytokine levels in culture supernatants from cells that
had been restimulated in vitro with virus-infected irradi-
ated antigen-presenting cells were assayed by sandwich
ELISA as described previously (Sarawar and Doherty,
1994). All reagents were obtained from PharMingen.
Statistical analysis
Data were analyzed using the Mann-Whitney rank sum
test.
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